These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8493423)

  • 41. Are safety committees really safe?
    Bergqvist D; Forbes CD; Minder CE; Planes A; Cate JW
    Scott Med J; 1998 Apr; 43(2):42-4. PubMed ID: 9717203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010.
    Califf RM; Zarin DA; Kramer JM; Sherman RE; Aberle LH; Tasneem A
    JAMA; 2012 May; 307(17):1838-47. PubMed ID: 22550198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of data monitoring committees in Canadian trial groups.
    Pater JL
    Stat Med; 1993 Mar; 12(5-6):505-8. PubMed ID: 8493428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Waivers proposed for emergency studies.
    Wolfgang L
    Science; 1995 Oct; 270(5233):25-6. PubMed ID: 7569946
    [No Abstract]   [Full Text] [Related]  

  • 45. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and data monitoring committees for clinical trials.
    Conti CR
    Clin Cardiol; 1995 Aug; 18(8):432. PubMed ID: 7586759
    [No Abstract]   [Full Text] [Related]  

  • 47. Panel discussion 2.
    Lan G; Lindborg S; Neaton J
    Clin Trials; 2012 Dec; 9(6):736-40. PubMed ID: 23250944
    [No Abstract]   [Full Text] [Related]  

  • 48. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trials. Fisher clashes with NCI--again.
    Marshall E
    Science; 1995 Feb; 267(5200):954. PubMed ID: 7863336
    [No Abstract]   [Full Text] [Related]  

  • 50. Rapid reporting and review of an increased incidence of a known adverse event.
    Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
    J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
    [No Abstract]   [Full Text] [Related]  

  • 51. Balancing caution & courage. Physicians and regulators weigh informed consent issues in clinical research.
    Montague J
    Hosp Health Netw; 1994 Sep; 68(18):50, 52-4. PubMed ID: 8081420
    [No Abstract]   [Full Text] [Related]  

  • 52. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Shutdown of research at Duke sends a message.
    Marshall E
    Science; 1999 May; 284(5418):1246. PubMed ID: 10383299
    [No Abstract]   [Full Text] [Related]  

  • 54. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Data Monitoring Committees - Expect the Unexpected.
    DeMets DL; Ellenberg SS
    N Engl J Med; 2016 Oct; 375(14):1365-1371. PubMed ID: 27705256
    [No Abstract]   [Full Text] [Related]  

  • 56. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NCI begins overhaul of late-stage cancer trials.
    Ault A
    Nat Med; 1998 Nov; 4(11):1219. PubMed ID: 9809532
    [No Abstract]   [Full Text] [Related]  

  • 59. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
    Dilts DM; Sandler AB; Baker M; Cheng SK; George SL; Karas KS; McGuire S; Menon GS; Reusch J; Sawyer D; Scoggins M; Wu A; Zhou K; Schilsky RL;
    J Clin Oncol; 2006 Oct; 24(28):4553-7. PubMed ID: 17008694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.